LUMO Earnings & Forecasts - Benzinga

SPY769.86+0.03%QQQ749.55−0.00%BTC/USD85,296.87+0.65%DIA511.70+0.12%GLD380.52+0.10%TLT77.53+0.06%

LUMO

LUMONasdaq Private Market

Private market price is not available

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

LUMO Earnings & Forecasts - Benzinga

LUMO Earnings & Forecasts

LUMO (LUMO) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Revenue (Billions)

LUMO Guidance

Recent Earnings Results

Metric	Q3 '24	Q2 '24	Q1 '24	Q4 '23
Earnings Per Share (Non-GAAP)
Estimate	$-0.82	$-1.24	$-1.18	$-1.15
Actual	$-0.90	$-0.93	$-1.29	$-1.17
Surprise	-9.76%	+25.0%	-9.32%	-1.74%
Revenue
Estimate	$200000	$330000	$300000	—
Actual	$726000	$488000	$165000	$826000
Surprise	+263.0%	+47.9%	-45.0%	—

Earnings & Guidance News

PRO
Lumos Pharma Q2 2024 GAAP EPS $(0.93) Beats $(1.24) Estimate, Sales $488.000K Beat $333.333K Estimate

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.24) by 25 percent. This is a 14.68 percent increase over losses of $(1.09) per share from the

Benzinga Newsdesk

PRO
Lumos Pharma Q1 2024 GAAP EPS $(1.29) Misses $(1.18) Estimate, Sales $165.00K Miss $302.60K Estimate

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18) by 9.32 percent. The company reported quarterly sales of $165.00 thousand which missed the

Benzinga Newsdesk

Lumos Pharma: Q4 Earnings Insights

Benzinga Insights

PRO
Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.170) per share which missed the analyst consensus estimate of $(1.150) by 1.74 percent. The company reported quarterly sales of $826.000 thousand which beat

Benzinga Newsdesk

Earnings Scheduled For March 7, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Benzinga Insights

Earnings Preview: Lumos Pharma

Benzinga Insights

Quarterly Earnings Surprise Amount

Fiscal Quarter	Date Reported	Actual EPS	Estimated EPS	Surprise %
Q3	Nov 7, 2024	$-0.90	$-0.82	-9.76 %
Q2	Aug 1, 2024	$-0.93	$-1.24	25.0 %
Q1	May 14, 2024	$-1.29	$-1.18	-9.32 %
Q4	Mar 7, 2024	$-1.17	$-1.15	-1.74 %

Quarterly Revenue Surprise Amount

Fiscal Quarter	Date Reported	Actual Revenue	Estimated Revenue	Surprise %
Q3	Nov 7, 2024	$726.00K	$200.00K	263.0 %
Q2	Aug 1, 2024	$488.00K	$330.00K	47.9 %
Q1	May 14, 2024	$165.00K	$300.00K	-45.0 %
Q3	Nov 7, 2023	$7.00K	$320.00K	-97.8 %